argenx Cash Flow Statement
NASDAQ: ARGXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
825.03+6.40 (+0.78%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
argenx free cash flow
In fiscal 2025, argenx generated $685.2 million of operating cash flow and spent $6.2 million on capital expenditures. That left free cash flow of $679.0 million.
Summary generated from market data by MetaCap's automated system. Methodology
argenx cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 |
|---|---|---|---|---|---|---|---|---|
| Net Income | 1.29B | 833.04M | -295.05M | -709.59M | -408.26M | -608.46M | -181.21M | -66.64M |
| Net Income growth (YoY) | +55.10% | — | — | — | — | — | — | — |
| Stock-Based Compensation | 248.08M | 235.18M | 232.97M | 157.03M | 179.37M | 96.93M | 44.24M | — |
| Operating Cash Flow | 685.19M | -82.75M | -420.33M | -862.81M | -606.81M | -398.46M | 151.63M | — |
| Capital Expenditures | -6.17M | -1.80M | -812.00K | -837.00K | -3.62M | -1.07M | -1.80M | — |
| Investing Cash Flow | 984.00M | -717.59M | 308.21M | -461.18M | -347.07M | 344.69M | -833.27M | — |
| Financing Cash Flow | 233.01M | 279.76M | 1.34B | 843.76M | 1.12B | 833.00M | 733.73M | — |
| Free Cash Flow | 679.03M | -84.55M | -421.14M | -863.64M | -610.43M | -399.53M | 149.83M | — |
This table shows 8 annual periods of argenx's cash flow statement, from FY 2025 back to FY 2018, across 7 line items including net income, stock-based compensation, operating cash flow. Values in USD; B = billions, M = millions. Fiscal periods follow ARGX's reporting calendar. What is a cash flow statement?